BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsFDA / regulatory

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS) FDA feedback confirms that the

Related news

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

REGNRegeneron Pharmaceuticals2026-06-22 11:00 EST

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

HCWBHCW Biologics2026-07-23 12:00 EST

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

IFRXInflarx NV2026-06-30 11:30 EST

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

INMBINmune Bio2026-06-25 11:00 EST

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

View all latest news

MoonLake Immunotherapeutics

Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding. Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting...

Recent company news

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Stock data

Close
15.76 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States